Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedAug 25, 2025
DataAggregated Company Financials
Companies9
  • 7D2.0%
  • 3M6.4%
  • 1Y0.05%
  • YTD9.9%

Novartis is up 2.5%, leading the way for the Pharma industry, which has gained 2.4%. The industry has been flat over the past 12 months despite the gain this week. As for the next few years, earnings are expected to grow by 13% per annum.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 25 Aug 2025CHF 480.6bCHF 120.5bCHF 21.0b31.1x22.9x4x
Wed, 23 Jul 2025CHF 436.8bCHF 118.5bCHF 19.5b24.4x22.4x3.7x
Fri, 20 Jun 2025CHF 445.7bCHF 118.6bCHF 19.2b25x23.3x3.8x
Sun, 18 May 2025CHF 432.1bCHF 120.1bCHF 19.5b25x22.2x3.6x
Tue, 15 Apr 2025CHF 406.4bCHF 117.1bCHF 18.4b24.2x22.1x3.5x
Thu, 13 Mar 2025CHF 478.3bCHF 121.6bCHF 19.1b29.5x25x3.9x
Sat, 08 Feb 2025CHF 474.0bCHF 123.1bCHF 19.3b22.7x24.6x3.9x
Mon, 06 Jan 2025CHF 429.0bCHF 119.6bCHF 21.4b18x20x3.6x
Wed, 04 Dec 2024CHF 432.9bCHF 118.1bCHF 21.2b18.5x20.5x3.7x
Fri, 01 Nov 2024CHF 452.3bCHF 116.7bCHF 20.9b19.6x21.6x3.9x
Sun, 29 Sep 2024CHF 457.4bCHF 114.3bCHF 19.2b21.9x23.8x4x
Tue, 27 Aug 2024CHF 474.1bCHF 114.7bCHF 19.3b22.6x24.6x4.1x
Thu, 25 Jul 2024CHF 451.7bCHF 116.6bCHF 20.5b32.6x22x3.9x
Sat, 22 Jun 2024CHF 432.4bCHF 116.2bCHF 19.7b33.9x21.9x3.7x
Mon, 20 May 2024CHF 417.8bCHF 113.3bCHF 19.9b40.3x21x3.7x
Wed, 17 Apr 2024CHF 402.3bCHF 112.6bCHF 19.5b37.3x20.7x3.6x
Fri, 15 Mar 2024CHF 380.6bCHF 110.6bCHF 19.7b23.4x19.3x3.4x
Sun, 11 Feb 2024CHF 377.4bCHF 110.0bCHF 19.6b24.1x19.2x3.4x
Tue, 09 Jan 2024CHF 413.7bCHF 119.1bCHF 18.6b27x22.2x3.5x
Thu, 07 Dec 2023CHF 398.7bCHF 120.8bCHF 18.8b24.5x21.2x3.3x
Sat, 04 Nov 2023CHF 384.3bCHF 122.3bCHF 19.1b23.4x20.2x3.1x
Mon, 02 Oct 2023CHF 407.6bCHF 113.6bCHF 18.2b44.4x22.4x3.6x
Wed, 30 Aug 2023CHF 409.1bCHF 111.8bCHF 17.9b48.1x22.8x3.7x
Fri, 28 Jul 2023CHF 418.9bCHF 114.4bCHF 19.2b48.5x21.8x3.7x
Sun, 25 Jun 2023CHF 425.0bCHF 115.2bCHF 18.9b37.3x22.5x3.7x
Tue, 23 May 2023CHF 434.6bCHF 115.3bCHF 18.9b39.7x23x3.8x
Thu, 20 Apr 2023CHF 434.6bCHF 114.9bCHF 18.8b42.6x23.1x3.8x
Sat, 18 Mar 2023CHF 384.7bCHF 116.4bCHF 19.1b25.6x20.2x3.3x
Mon, 13 Feb 2023CHF 407.7bCHF 116.2bCHF 19.0b29.1x21.4x3.5x
Wed, 11 Jan 2023CHF 432.3bCHF 117.0bCHF 34.6b22.5x12.5x3.7x
Fri, 09 Dec 2022CHF 445.3bCHF 117.7bCHF 34.9b23x12.8x3.8x
Sun, 06 Nov 2022CHF 456.4bCHF 120.9bCHF 36.2b22.8x12.6x3.8x
Tue, 04 Oct 2022CHF 443.1bCHF 121.1bCHF 37.3b20.2x11.9x3.7x
Thu, 01 Sep 2022CHF 444.3bCHF 120.2bCHF 36.9b21.1x12.1x3.7x
Price to Earnings Ratio

12.1x


Total Market Cap: CHF 444.3bTotal Earnings: CHF 36.9bTotal Revenue: CHF 120.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 20.6x202320242025
Current Industry PE
  • Investors are optimistic on the Swiss Pharmaceuticals industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 22.9x which is higher than its 3-year average PE of 20.6x.
  • The industry is trading close to its 3-year average PS ratio of 3.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 17% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market1.55%
Healthcare1.27%
Pharma1.96%
Pharma1.96%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ROG Roche HoldingCHF 259.901.5%
+CHF 3.3b		-8.8%PE23.4x
NOVN NovartisCHF 101.241.0%
+CHF 2.0b		0.4%PE17.9x
SDZ Sandoz GroupCHF 50.544.7%
+CHF 969.1m		34.8%PE119.5x
GALD Galderma GroupCHF 137.102.5%
+CHF 807.2m		67.1%PE107.3x
NWRN Newron PharmaceuticalsCHF 8.5921.7%
+CHF 30.5m		8.5%PE11.5x

Latest News

NWRN
CHF 8.59
Newron Pharmaceuticals
7D
21.7%
1Y
8.5%
GALD
CHF 137.10
Galderma Group
7D
2.5%
1Y
67.1%

Is Galderma Group (VTX:GALD) A Risky Investment?

Aug 24
Is Galderma Group (VTX:GALD) A Risky Investment?
ROG
CHF 259.90
Roche Holding
7D
1.5%
1Y
-8.8%

Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)

Aug 20
Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)
SDZ
CHF 50.54
Sandoz Group
7D
4.7%
1Y
34.8%

Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities

Key Takeaways Accelerated biosimilar launches, improved manufacturing, and strong market share are driving margin expansion and long-term profitability. Strategic focus on international growth and a robust product pipeline positions the company for sustainable earnings momentum.
DESN
CHF 291.50
Dottikon ES Holding
7D
-2.5%
1Y
12.3%

Does Dottikon ES Holding (VTX:DESN) Have A Healthy Balance Sheet?

Aug 13
Does Dottikon ES Holding (VTX:DESN) Have A Healthy Balance Sheet?
NOVN
CHF 101.24
Novartis
7D
1.0%
1Y
0.4%
ADXN
CHF 0.056
Addex Therapeutics
7D
-4.4%
1Y
-6.4%
COPN
CHF 58.30
Cosmo Pharmaceuticals
7D
2.1%
1Y
-25.8%
BIOV
CHF 24.90
BioVersys
7D
-2.0%
1Y
n/a